Biogen Inc. stock reaches a new 52-week high

Published on 09/23/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen Inc. stock closed at USD 224.87 on September 22, 2026, after a 2.7 percent gain. Adjusted EPS reached USD 3.60 in Q2 2026.

Fotorealistisches Biotech-Labor in Cambridge MA mit Forscherin am Mikroskop und Blick auf den Charles River — Biogen Inc. Neurowissenschaftslabor in Cambridge MA zeigt Forscherin bei Gehirngewebeanalyse unter Mikroskop ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) closed at USD 224.87 on the Nasdaq on September 22, 2026, up 2.7 percent from the prior close. The session high of USD 226.43 set a new 52-week high, giving the stock a clear market signal ahead of its next pipeline updates.

Pipeline expectations support the stock

According to Investing.com on September 22, 2026, RBC Capital raised its Biogen price target from USD 240 to USD 260, citing the potential of the lupus drug litifilimab. H.C. Wainwright increased its target from USD 237 to USD 251, while Piper Sandler raised its target from USD 225 to USD 245 after updating its model following the second quarter.

The target changes are tied to development prospects rather than the September 22 closing price alone. Litifilimab therefore remains a central valuation variable, while the upcoming clinical readouts could determine whether the stock can hold its new yearly high.

Second quarter beat expectations

Biogen reported adjusted earnings per share of USD 3.60 for the second quarter of 2026, compared with analyst expectations of USD 2.94, a positive difference of USD 0.66. Revenue reached USD 2.74 billion versus the USD 2.46 billion consensus, while revenue increased 3.4 percent from the same quarter a year earlier, according to MarketBeat in its September 22, 2026 report.

The company set fiscal-year 2026 adjusted EPS guidance at USD 12.00 to USD 13.00. That range gives the market a measurable earnings framework, but the comparison with the prior-year quarterly EPS of USD 5.47 also shows how much period effects can influence the reported result.

Stock trades near its yearly peak

Biogen shares traded between USD 219.07 and USD 226.43 on September 22, 2026, with volume of 262,187 shares. The closing price was only USD 1.56 below the session high, while the prior close was USD 219.07, according to the Nasdaq trading data reported by MarketBeat.

The company had a market capitalization of about USD 33.26 billion on September 22, 2026. Biogen is classified as a Health Care and Biotechnology company, trades under the ticker BIIB on the Nasdaq, and is included in the Nasdaq 100.

Biogen Inc. stock closes at USD 224.87

Biogen Inc. stock closed at USD 224.87 on the Nasdaq on September 22, 2026, after rising 2.7 percent from the previous close. The USD 226.43 session high was also the new 52-week high, keeping pipeline progress and the fiscal-year EPS range central to the valuation discussion.